Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Case Report: Cytokine adsorption during multimodal management of hyperinflammatory toxicities following CAR-T in three patients.

Created on 13 Nov 2026

Authors

Haoran Xu, Fangce Wang, Yuqiu Lu, Wenjun Zhang, Yingying Zhang, Aibin Liang

Published in

Frontiers in immunology. Volume 17. Pages 1968648. Epub Oct 29, 2026.

Abstract

Chimeric antigen receptor T cell (CAR-T) has advanced rapidly in hematologic malignancies and even solid tumors, but post-treatment adverse reactions remain a major risk. Most adverse reactions are associated with inflammatory responses and cytokine release, such as cytokine release syndrome. Cytokine adsorption is an extracorporeal blood-purification approach designed to adsorb circulating inflammatory mediators. We report three patients with CAR-T-associated CRS, CRS with ICANS, or CRS with IEC-HS who received CA330-based cytokine adsorption as part of multimodal management. Clinical recovery and reductions in selected inflammatory markers were observed during the treatment course, and no procedure-related adverse events were documented. However, because adsorption overlapped with anti-IL-6 therapy, corticosteroids, anti-infective and supportive care, and the natural evolution of these toxicities, its independent contribution could not be determined. These observations support the feasibility of this approach and warrant prospective evaluation.

PMID:
43021944
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement